假性动脉瘤形成及再干预必要性的相关因素:单中心研究
回顾性分析2011年2月至2017年4月外周假性动脉瘤介入治疗的超声和CT血管造影资料,纳入99例患者。主要再干预危险因素为干预前血小板减少症,血管外科术后假性动脉瘤及较大鞘管尺寸和动脉闭合装置也有正相关趋势。华法林组假性动脉瘤囊腔更大,溶栓所需凝血酶剂量与囊腔增大正相关。
要点
- 干预前血小板减少(<150×10^9/L)是再干预的主要危险因素(p=0.025)。
- 血管外科术后假性动脉瘤再干预风险较高(p=0.033)。
- 华法林组假性动脉瘤囊腔均值大于未治疗、阿司匹林和氯吡格雷组。
核心结论
- 再干预的主要危险因素是干预前血小板减少症,其他正相关因素包括血管外科术后假性动脉瘤、较大鞘管尺寸和动脉闭合装置。华法林化患者囊腔更大的假性动脉瘤,且溶栓所需凝血酶剂量更高与囊腔增大正相关。
研究设计与样本
- 回顾性分析2011年2月至2017年4月外周假性动脉瘤介入治疗的超声扫描和CT血管造影资料,纳入99例患者(61.6%女性),中位年龄72岁(范围12-89岁)。
关键影像表现/征象
- 假性动脉瘤部位以股总动脉为主(62.6%)。
- 华法林组假性动脉瘤囊腔均值4.21 cm(范围0.9-7.6),大于未治疗组(p=0.003)、阿司匹林组(p=0.005)和氯吡格雷组(p=0.026)。
诊断标准与关键数值
- 血管介入放射学相关假性动脉瘤发生率为0.48%(31/6451),心内科为0.24%(60/25,229)。
- 超声引导下凝血酶注射(UGTI)初次成功率98.9%、即刻并发症3.0%、30天死亡率2.0%、再干预率11.8%。
- 外科修复初次成功率100%、即刻并发症0.0%、30天死亡率22.2%、再干预率16.7%。
临床应用与阅片要点
- 干预前血小板减少(<150×10^9/L)和血管外科术后假性动脉瘤患者可能受益于干预后影像监测,因再干预风险显著。
- 使用鞘管尺寸>6 Fr(p=0.108)或动脉闭合装置(p=0.111)与再干预呈正相关但未达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Evaluate the factors associated with pseudoaneurysm development and morphology. Measure ultrasound-guided thrombin injection (UGTI) and surgical treatment outcomes for pseudoaneurysms, and the necessity for post-primary intervention (reintervention).
METHODS: Retrospective analysis of ultrasound scans and CT angiography of peripheral pseudoaneurysm interventions from February 2011 to April 2017. 99 patients (61.6% female) were identified; median age 72 years (range 12-89). Multivariate analysis of patient demographics, including pre-intervention anticoagulant and antiplatelet medication was performed.
RESULTS: Primary intervention for peripheral pseudoaneurysms (62.6% common femoral artery) included 93 UGTI and 6 surgical repairs; with 12 reinterventions (9 UGTI and 3 surgical). Pseudoaneurysm incidence for vascular interventional radiology (VIR) was 0.48% (31/6451) and cardiology was 0.24% (60/25,229). Rates for primary success, immediate complications, 30-day mortality and reintervention were measured respectively for UGTI (98.9%, 3.0%, 2.0%, and 11.8%) and surgical repair (100%, 0.0%, 22.2% and 16.7%). Reintervention risk factors included pre-intervention thrombocytopaenia (<150 × 109/L) ( p = 0.025) and pseudoaneurysms following vascular surgery (p = 0.033). Other positive associations for reintervention (non-significant) included use of a sheath size > 6 Fr ( p = 0.108) or arterial closure device ( p = 0.111) during the pseudoaneurysm causative procedure. The pre-intervention warfarin subgroup developed a larger mean pseudoaneurysm sac size (4.21 cm, range 0.9-7.6), compared to no treatment (p = 0.003), aspirin (p = 0.005) and clopidogrel (p = 0.026) subgroups. UGTI dosage for thrombosis had a positive correlation with incremental sac size increase (p < 0.001).
CONCLUSION: The main reintervention risk factor was pre-intervention thrombocytopaenia, with additional positive associations including pseudoaneurysms caused by surgery, increased sheath size and arterial closure devices. Warfarinized patients developed larger sac-sized pseudoaneurysms compared with other pre-intervention regimens, with positive correlation of higher UGTI dosage required for thrombosis.
ADVANCES IN KNOWLEDGE: Patients with pre-intervention thrombocytopaenia and pseudoaneurysms attributed to vascular surgery are subgroups that may benefit from post-intervention imaging surveillance due to significant reintervention risk.
引用
- Delf J, Ramachandran S, Mustafa S, et al. Factors associated with pseudoaneurysm development and necessity for reintervention: a single centre study. Br J Radiol. 2019. PMID: 30982331. doi:10.1259/bjr.20180893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。